Investigating a new treatment approach for advanced prostate cancer
Official title: A translational study of a synthetic lethality interaction of CD105 and androgen receptor signaling axis for castration-resistant prostate cancer patients
Funded at Cedars-Sinai Medical Center · NIH-10943867 · Data updated 2026-11-12
This study is looking at a new way to help men with castration-resistant prostate cancer by using a combination of two treatments to see if they can work better together and improve how well the cancer responds to therapy.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cedars-Sinai Medical Center NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project start | July 1, 2024 |
| Project end | June 30, 2029 |
| Funding year | 2024 |
| Award (this year) | $553,550 |
| NIH project number | 1R01CA292654-01 |
| Project ID | NIH-10943867 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are men diagnosed with castration-resistant prostate cancer who have not responded to standard androgen receptor signaling inhibitors.
✕Less likely to help
Patients with early-stage prostate cancer or those who have not yet undergone treatment may not benefit from this research.
What this research studies
This research aims to explore a novel treatment strategy for patients with castration-resistant prostate cancer by combining androgen receptor signaling inhibitors with a CD105 antagonist called carotuximab. The study focuses on understanding how this combination can overcome resistance to standard therapies, which often fail over time. By examining the interactions between these treatments and the tumor environment, researchers hope to identify effective ways to enhance treatment responses in patients. The approach involves both laboratory studies and clinical trials to assess safety and efficacy.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options for patients with advanced prostate cancer who have become resistant to current therapies.
How similar studies have gone: Previous studies have shown promise in combining targeted therapies for prostate cancer, suggesting that this approach may yield beneficial results.
Where this research is happening
-
Cedars-Sinai Medical Center
Los Angeles, United States Active
Researchers
- Principal investigator: Bhowmick, Neil a. — Cedars-Sinai Medical Center
- Study coordinator: Bhowmick, Neil a.
Related research
Other NIH-funded projects on the same topics.
-
Understanding how aggressive cell states emerge in castration-resistant prostate cancer
A research project aims to uncover the hidden cell states that help prostate cancer resist standard therapy and how these states arise early in tumor development.
-
Enhancer RNA CYP11A1-eRNA in castration-resistant prostate cancer
Researchers are testing a new RNA-based target, CYP11A1-eRNA, to see if blocking it can hamper the growth of castration-resistant prostate cancer in the lab and animal models.
-
Targeted Immunostimulatory Dual Drug Conjugates for Heterogeneous Metastatic Prostate Cancer
Researchers are testing a targeted therapy approach to help people with metastatic castration-resistant prostate cancer by boosting the immune system and delivering drugs directly to cancer cells.
-
Androgen Receptor Action in Prostate Cancer that Stops Responding to Therapy
This grant supports research to understand why certain prostate cancers stop responding to AR-targeted therapies and to find new ways to target them.
-
Hyperactive methylation in a hard-to-treat prostate cancer subtype
Researchers are studying a newly identified methylation-heavy group of advanced prostate cancer to understand its biology and find clues for better treatments.
-
Therapeutic Targeting of Lineage Plasticity in Advanced Prostate Cancer
A cancer research effort aimed at understanding and tackling how aggressive prostate cancers become resistant to standard AR-targeted therapies.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.